These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 39389721)

  • 1. Real-World Studies of Biologics for the Treatment of Moderate-to-Severe Asthma.
    Desai M; Haines A; Oppenheimer JJ
    Immunol Allergy Clin North Am; 2024 Nov; 44(4):737-750. PubMed ID: 39389721
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety of Biological Therapies for Severe Asthma: An Analysis of Suspected Adverse Reactions Reported in the WHO Pharmacovigilance Database.
    Cutroneo PM; Arzenton E; Furci F; Scapini F; Bulzomì M; Luxi N; Caminati M; Senna G; Moretti U; Trifirò G
    BioDrugs; 2024 May; 38(3):425-448. PubMed ID: 38489062
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mabs for treating asthma: omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab.
    Ridolo E; Pucciarini F; Nizi MC; Makri E; Kihlgren P; Panella L; Incorvaia C
    Hum Vaccin Immunother; 2020 Oct; 16(10):2349-2356. PubMed ID: 32401603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma.
    Agache I; Beltran J; Akdis C; Akdis M; Canelo-Aybar C; Canonica GW; Casale T; Chivato T; Corren J; Del Giacco S; Eiwegger T; Firinu D; Gern JE; Hamelmann E; Hanania N; Mäkelä M; Hernández-Martín I; Nair P; O'Mahony L; Papadopoulos NG; Papi A; Park HS; Pérez de Llano L; Posso M; Rocha C; Quirce S; Sastre J; Shamji M; Song Y; Steiner C; Schwarze J; Alonso-Coello P; Palomares O; Jutel M
    Allergy; 2020 May; 75(5):1023-1042. PubMed ID: 32034960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biologics in allergic rhinitis.
    Bayar Muluk N; Cingi C
    Eur Rev Med Pharmacol Sci; 2023 Oct; 27(5 Suppl):43-52. PubMed ID: 37869947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of Biologics in Patients with Allergic Severe Asthma, Overall and by Blood Eosinophil Count: A Literature Review.
    Bernstein JA; Llanos JP; Hunter G; Martin N; Ambrose CS
    Adv Ther; 2023 Nov; 40(11):4721-4740. PubMed ID: 37698716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Asthma Biologics: Lung Function, Steroid-Dependence, and Exacerbations.
    Salciccioli JD; Israel E
    Immunol Allergy Clin North Am; 2024 Nov; 44(4):693-708. PubMed ID: 39389718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tezepelumab compared with other biologics for the treatment of severe asthma: a systematic review and indirect treatment comparison.
    Menzies-Gow A; Steenkamp J; Singh S; Erhardt W; Rowell J; Rane P; Martin N; Ackert JL; Quinton A
    J Med Econ; 2022; 25(1):679-690. PubMed ID: 35570578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative Impact of Asthma Biologics: A Nationwide US Claim-Based Analysis.
    Al-Shaikhly T; Norris MR; Dennis EH; Liu G; Craig TJ
    J Allergy Clin Immunol Pract; 2024 Jun; 12(6):1558-1567. PubMed ID: 38423294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Global Variability in Administrative Approval Prescription Criteria for Biologic Therapy in Severe Asthma.
    Porsbjerg CM; Menzies-Gow AN; Tran TN; Murray RB; Unni B; Audrey Ang SL; Alacqua M; Al-Ahmad M; Al-Lehebi R; Altraja A; Belevskiy AS; Björnsdóttir US; Bourdin A; Busby J; Canonica GW; Christoff GC; Cosio BG; Costello RW; FitzGerald JM; Fonseca JA; Hansen S; Heaney LG; Heffler E; Hew M; Iwanaga T; Jackson DJ; Kocks JWH; Kallieri M; Bruce Ko HK; Koh MS; Larenas-Linnemann D; Lehtimäki LA; Loukides S; Lugogo N; Maspero J; Papaioannou AI; Perez-de-Llano L; Pitrez PM; Popov TA; Rasmussen LM; Rhee CK; Sadatsafavi M; Schmid J; Siddiqui S; Taillé C; Taube C; Torres-Duque CA; Ulrik C; Upham JW; Wang E; Wechsler ME; Bulathsinhala L; Carter V; Chaudhry I; Eleangovan N; Hosseini N; Rowlands MA; Price DB; van Boven JFM
    J Allergy Clin Immunol Pract; 2022 May; 10(5):1202-1216.e23. PubMed ID: 34990866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical characteristics of complete responders versus non-complete responders to omalizumab, benralizumab and mepolizumab in patients with severe asthma: a long-term retrospective analysis.
    Basagaña M; Martínez-Rivera C; Padró C; Garcia-Olivé I; Martínez-Colls M; Navarro J; Pardo L; Cruz P; Cardona Peitx G; Carabias L; Roger A; Abad J; Rosell A
    Ann Med; 2024 Dec; 56(1):2317356. PubMed ID: 38364218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence of Anti-Drug Antibodies to Monoclonal Antibodies in Asthma: A Systematic Review and Meta-Analysis.
    Chen ML; Nopsopon T; Akenroye A
    J Allergy Clin Immunol Pract; 2023 May; 11(5):1475-1484.e20. PubMed ID: 36716995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biological treatments in childhood asthma.
    Nieto-García A; Nieto-Cid M; Mazón-Ramos Á
    Curr Opin Allergy Clin Immunol; 2024 Jun; 24(3):114-121. PubMed ID: 38567842
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Omalizumab as alternative to chronic use of oral corticosteroids in severe asthma.
    Katsaounou P; Buhl R; Brusselle G; Pfister P; Martínez R; Wahn U; Bousquet J
    Respir Med; 2019 Apr; 150():51-62. PubMed ID: 30961951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness analysis of dupilumab among patients with oral corticosteroid-dependent uncontrolled severe asthma in Japan.
    Tohda Y; Matsumoto H; Miyata M; Taguchi Y; Ueyama M; Joulain F; Arakawa I
    J Asthma; 2022 Nov; 59(11):2162-2173. PubMed ID: 34752208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative efficacy of tezepelumab to mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: A Bayesian network meta-analysis.
    Nopsopon T; Lassiter G; Chen ML; Alexander GC; Keet C; Hong H; Akenroye A
    J Allergy Clin Immunol; 2023 Mar; 151(3):747-755. PubMed ID: 36538979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world efficacy of treatment with benralizumab, dupilumab, mepolizumab and reslizumab for severe asthma: A systematic review and meta-analysis.
    Charles D; Shanley J; Temple SN; Rattu A; Khaleva E; Roberts G
    Clin Exp Allergy; 2022 May; 52(5):616-627. PubMed ID: 35174566
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity of biologics used in the treatment of asthma.
    Neunie OAM; Rabbani W; Baker D; Chambers ES; Pfeffer PE; Kang AS
    Hum Antibodies; 2024; 32(3):121-128. PubMed ID: 38905039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Biologics for the treatment of severe asthma: Current status report 2023].
    Paçacı Çetin G; Kepil Özdemir S; Can Bostan Ö; Öztop N; Çelebi Sözener Z; Karakaya G; Gelincik Akkor A; Yılmaz İ; Mungan D; Bavbek S
    Tuberk Toraks; 2023 Jun; 71(2):176-187. PubMed ID: 37345400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biologics for oral corticosteroid-dependent asthma.
    Yılmaz İ
    Allergy Asthma Proc; 2020 May; 41(3):151-157. PubMed ID: 32375958
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.